CD28 Blockade Bioassay Components
The assay consists of two genetically engineered cell lines:
CD28 Effector Cells: Jurkat T cells expressing endogenous TCR/CD3 and CD28, and a luciferase reporter driven by TCR/CD3 and CD28 pathway-dependent response elements.
aAPC/Raji Cells: Raji cells expressing an engineered cell surface protein designed to activate TCR/CD3 in an antigen-independent manner and endogenously expressing the B7 ligands.
The CD28 Effector Cells and aAPC/Raji Cells are also available in Cell Propagation Model format (CPM; Cat.# JA7072) as cryopreserved cells that can be thawed, propagated and banked for long-term use.
When the two cell types are co-cultured, the aAPC/Raji Cells activate TCR/CD3 and CD28 on the Effector Cells to induce maximum promoter-mediated luminescence. Addition of a biologic that blocks CD28/B7 inhibits co-stimulation by CD28 and results in decreased promoter-mediated luminescence.